
Arpolax20 mg
Incepta Pharmaceuticals Ltd.
Established / FDA-Approved Use Major Depressive Disorder (MDD) in adults : Citalopram Hydrobromide is FDA-approved for the acute and maintenance treatment of major depressive disorder in adult…
Citalopram Hydrobromide is not FDA-approved for the indications below, but is supported by clinical evidence and commonly prescribed off-label by physicians, usually after first-line options are considered:
Use for these off-label indications should be individualized and directed by a qualified physician.
| Population | Recommended Dosing |
|---|---|
| Standard adults | Initiate at 20 mg once daily; may increase to a maximum of 40 mg once daily after a minimum of one week, based on response and tolerability |
| Patients >60 years (elderly) | Maximum recommended dose is 20 mg once daily |
| Hepatic impairment | Maximum recommended dose is 20 mg once daily |
| Known CYP2C19 poor metabolizers | Maximum recommended dose is 20 mg once daily |
| Concomitant use with a CYP2C19 inhibitor (e.g., omeprazole, esomeprazole, cimetidine, fluconazole) | Maximum recommended dose is 20 mg once daily |
Doses above 40 mg/day are not recommended in any population because of dose-dependent QT interval prolongation and associated risk of torsades de pointes; this is a boxed-warning-level safety concern. See Precautions and Warnings.
When used off-label for panic disorder, a lower starting dose (e.g., 10 mg once daily) is typically used for the first week to reduce the risk of early treatment-emergent anxiety, then increased gradually as tolerated, again not exceeding the maximum doses above for the relevant population.
No dose adjustment is generally required in mild-to-moderate renal impairment; caution and lower doses are advised in severe renal impairment.
Safety and effectiveness have not been established in pediatric patients; Citalopram Hydrobromide is not recommended for use in this population outside specialist supervision. See Use in Special Populations.
Citalopram Hydrobromide should not be stopped abruptly after regular use; the dose should be tapered gradually under medical supervision to reduce the risk of discontinuation symptoms. See Precautions and Warnings.
| System | Effects |
|---|---|
| Gastrointestinal | Nausea, dry mouth, diarrhea, decreased appetite |
| Neurological/Psychiatric | Somnolence, insomnia, tremor, dizziness |
| Other | Increased sweating, ejaculation disorder (delayed ejaculation), decreased libido |
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.